title: Immunotoxic effects of 2-bromopropane in male Sprague-Dawley rats: a 28-day exposure study.
abstract: Immunotoxic effects of 2-bromopropane were investigated in male Sprague-Dawley rats. The rats were treated orally daily with 2-bromopropane at 100, 330, or 1000 mg/kg for 28 consecutive days. Four days before necropsy, the rats were immunized intravenously with sheep red blood cells (SRBCs). The body and thymus weights were significantly reduced by treatment with 2-bromopropane at the highest dose. In addition, the numbers of splenic and thymic cells were decreased by 2-bromopropane. In hematology, the numbers of white blood cells, red blood cells, and platelets were significantly reduced. Among the serum clinical parameters, the levels of chloride ion were significantly increased by 2-bromopropane. The antibody response to SRBCs was significantly suppressed at the highest dose. With immunized animals, immunophenotyping of splenic and thymic cells was performed to investigate the changes of the number of macrophages, B cells, and T cells in spleen and the number of CD4+ and CD8+ cells in thymus. The numbers of most cell types were significantly decreased in the spleen when animals were treated with 2-bromopropane at 1,000 mg/kg. Likewise, all cell types of thymus were significantly decreased by 2-bromopropane. The present results suggest that 2-bromopropane may have an immunotoxic potential in male Sprague-Dawley rats when the rats are exposed for 28 d.
authors.affiliation: College of Pharmacy, Yeungnam University, Kyungbuk, South Korea. taecheon@yu.ac.kr
authors.forename: Tae Cheon
authors.initials: TC
authors.lastname: Jeong
authors.forename: Eung-Seok
authors.initials: ES
authors.lastname: Lee
authors.forename: Whigun
authors.initials: W
authors.lastname: Chae
authors.forename: Woo Suk
authors.initials: WS
authors.lastname: Koh
authors.forename: Boo-Hyon
authors.initials: BH
authors.lastname: Kang
authors.forename: Sang Seop
authors.initials: SS
authors.lastname: Han
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000917:Antibody Formation; D001402:B-Lymphocytes / Q000276:immunology; D015704:CD4 Antigens / Q000032:analysis; D016827:CD8 Antigens / Q000032:analysis; D004305:Dose-Response Relationship, Drug; D006842:Hydrocarbons, Brominated / Q000633:toxicity*; D007107:Immune System / Q000187:drug effects*; D016130:Immunophenotyping; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D012756:Sheep; D012997:Solvents / Q000633:toxicity*; D013601:T-Lymphocytes / Q000276:immunology; D013950:Thymus Gland / Q000276:immunology
chemical_list: D015704:CD4 Antigens; D016827:CD8 Antigens; D006842:Hydrocarbons, Brominated; D012997:Solvents; C103736:2-bromopropane